Sihuan Pharm (00460.HK) announced on June 13 that its non-wholly owned subsidiary, Xuanzhu Biopharmaceutical Technology Co., Ltd. ("Xuanzhu Biopharm"), had reached an exclusive licensing agreement with Livzon Pharmaceutical Group Inc.'s ("Livzon Pharma"; A-share stock code: 000513.SZ; listed in Hong Kong stock code: 01513) wholly-owned subsidiary Livzon Pharmaceutical Group Livzon Pharmaceutical Factory on the high-selective phosphodiesterase 5 ("PDE5") inhibitor Fudanafil (product code: XZP-5849) independently developed by Xuanzhu Biopharm.

According to the licensing agreement, Livzon Pharma will obtain the exclusive development, production and commercialization rights of Fudanafil (XZP-5849) active pharmaceutical ingredient and formulation in Greater China and non-regulatory market areas. Xuanzhu Biopharm will retain the development, production and commercialization rights of Fudanafil in Europe, the United States, Canada, Japan, South Korea, Australia and Brazil. Xuanzhu Biopharm will receive pre-payment and have the right to receive milestone payments and graded royalty sales after the product is listed.